# Dose-finding Study in Platinum-Resistant Ovarian Cancer

> **NCT01653912** · PHASE1,PHASE2 · COMPLETED · sponsor: **Accenture** · enrollment: 59 (actual)

## Conditions studied

- Recurrent Platinum-resistant Ovarian Cancer

## Interventions

- **DRUG:** GSK2110183 in combination with carboplatin and paclitaxel

## Key facts

- **NCT ID:** NCT01653912
- **Lead sponsor:** Accenture
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-07
- **Final completion:** 2015-11
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2018-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01653912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01653912, "Dose-finding Study in Platinum-Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01653912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*